Haemato-Oncology Network Site Specific Group Minutes
Thursday 15th October 2015
Arundel Arms Hotel, Lifton PL16 0DE
This meeting was sponsored by Alexion, Amgen, Gilead, Pfizer, Janssen and Roche.
Roche Products Limited has had no control over the educational content.
Attendees:
Patrick Medd, PHT (Chair)
Kerry McKay, PHT
Susan Gilbert, PHT
Adam Forbes, RCHT
Deborah Turner, SDHT
Clare Fox, RDE
Liz Boylan, PCN
Suzanne Greep, PHT
Rebecca Hick, PHT
Sophie Kendall, PHT
Linzi Retallick-Schmid, RCHT
Libby Hardy, SWSCN
Wendy Cook, PCRN
Mel Chandler, PCN
ACTION
1.
2.
2.1
2.2
2.3
2.4
2.5
2.6
2.7
3.
3.1
4.
4.1
4.2
5.
5.1
Welcome and Apologies
Patrick Medd chaired the meeting, he welcomed the group and apologies
were accepted.
Minutes/Actions of Meeting held 14TH May 2015
The minutes of the last meeting were reviewed and accepted by the
meeting.
Action from last meeting:
Catchment Population - the RDE and ND meeting the 500,000 requirement.
The number shown for RCHT is 534,000 for the whole of Cornwall which is
slightly high. Need to ascertain the official number for RCHT.
Action: AF to clarify the number on the table.
User Representation - complete as it was agreed we only need one i.e. we do
not require one from each MDT.
Pathology Leads have been confirmed as:Oncology – Chris Hamilton, RDE
Radiology – Richard Riordan, PHT
Pathology – Mark Smith,PHT
Videoconferencing - on hold. Remove item.
ARIA Pro-Forma - is completed at MDT. Remove item.
Innovation Funding – Dr Turner said Celgene not interested. Remove item.
Terms of Reference
Approved by members present.
Constitution
Approved by members present.
It was noted that Loretta Ngu and Clare Fox were the new Joint MDT leads
for RDE & ND.
Action: LB to update Constitution
LB
Clinical Guidelines
The group agreed to sign off the Clinical Haematological Malignancy
Haemato-oncology NSSG Minutes 15.10.15 draft v0.1
AF
6.
6.1
7.
7.1
8.
8.1
8.2
9.
9.1
10.
10.1
10.2
10.3
Guidelines 2015 that had been distributed with agenda as the Peninsula
Network Clinical Guidelines. There will be a 6-monthly review by the
following members for the next meeting.
Lymphoma – Deborah Turner
Myeloma – Adam Forbes
Chronic Lymphocytic Leukaemia – Jason Coppell
Chronic Myeloid Leukaemia – Patrick Medd
Acute Myeloid Leukaemia – Patrick Medd
Acute Lymphoblastic Leukaemia – Patrick Medd
Myodysplasia – Patrick Medd
Myeloproliferative Disorders – Patrick Medd
DT/AF/JC/PM
Action: DT/AF/JC/PM to send LB any updates to Clinical Guidelines prior to
next meeting
Patient Pathways
A sample Southwest 2WW Referral form has been circulated by Jonathan
Miller, South West Cancer Network Manager. LB has been asked by Sian
Dennison, PHT Cancer Services Manager, to present the current PHT 2WW
Referral Form which she had updated to meet the latest referral guidelines.
It was agreed we should look at a single network proforma for haematology
Action: Everyone to send their forms to LB and she will co-ordinate review.
ALL
Annual Report/Work Programme
The Annual Report and Work Programme were agreed.
Action: PM agreed to arrange a separate meeting to discuss SIHMDS with
the Patrick Roberts, Jason Coppell, Wayne Thomas, Bryson Pottinger, Mark
Smith, Nigel Oakes and Jo Farrugia.
Action: PM to provide feedback for next annual report.
PM
Patient Representative
PM welcomed Sophie Kendall to her first NSSG meeting as patient
representative and thanked her for her involvement. She said the treatment
she had received was “world class”.
WC said that patient representation and their input on clinical trials was
needed as they can give a “walk through” of their trial and say what they
would like to see from a patient’s point of view.
Audit
DT has Plymouth’s figures but is waiting for Truro’s. Conversion rates vary.
The Peninsula Cancer Network’s 2WW Audit form is attached to the back of
these minutes.
Action: DT to look at new figures and complete audit report.
DT
Research / Clinical Trials
DT had recently attended the Lymphoma Strategy SSG Group in London.
There appears to be many holes in the research portfolio with industry
holding trials in other countries but not the UK. We will probably need to do
more commercial studies.
All network leads did not know what their roles were. Getting varying
information. DT said she gets information quicker through the Trust than
through the Research Network as Haematology Subspecialty Lead. WC said
she would copy in the Sub Speciality Leads when she sends out research in
the future.
WC discussed financial penalties that will be applied if trusts to not meet the
recruitment targets they have set when commencing a trial.
Haemato-oncology NSSG Minutes 15.10.15 draft v0.1
10.4
11.
11.1
12.
12.1
13.
13.1
13.2
Action: WC to see if studies with very low targets could be excluded.
WC leaves her post on 27th November and will be replaced by Julie
Cunningham.
Living With & Beyond Cancer
Every trust has a Project Manager leading on this. DT is doing a health and
wellbeing event next week.
Action: LB to invite Wendi Abraham, Macmillan Patient Pathway Redesign
Project Manager, to attend next meeting
Action: CNS update from each trust for next meeting
Any Other Business
Peer Review – Some issues raised included:
Lack of Integrated Reports.
Attendance of Histopathologists/Radiologists/Oncologists at MDTs
Date of Next Meetings
Thursday 28th April 2016 at the Arundel Arms, Lifton prior to the Blood Club
meeting
Thursday 20th October 2016 at the Arundel Arms, Lifton prior to the Blood
Club meeting
Haemato-oncology NSSG Minutes 15.10.15 draft v0.1
WC
LB
CNS